

5. The composition of claim 4, further comprising a P285L mutation.

6. The composition of claim 1, wherein said mutation causes increased catalytic capacity of BChE towards the degradation of cholinesterase inhibitors as compared to wild-type human butyrylcholinesterase.

7. The composition of claim 1, further comprising one or more agents selected from atropine and 2-PAM

8. A method of treating organophosphate exposure in an individual in need thereof, comprising the step of administering a composition according to claim 1.

9. A method of treating organophosphate exposure in an individual in need thereof, comprising the step of administering a composition according to claim 1, wherein said composition is administered to said individual prophylactically.

10. An auto injector device comprising a composition according to claim 1.

11. A method of treating organophosphate exposure in an individual in need thereof, comprising the step of administering said composition to an individual using the autoinjector device of claim 10.

* * * * *